Full-Time
Posted on 9/2/2025
Ultrasound-guided nonviral gene therapy platform
$150k - $175k/yr
San Bruno, CA, USA
In Person
On-site required 4+ days per week.
SonoThera develops an ultrasound-guided nonviral gene therapy platform that uses microbubbles and sonoporation to deliver genetic medicines to different human organs. The system works by applying ultrasound to microbubble carriers, creating temporary pores in cell membranes to allow genetic material to enter cells without viral vectors. This approach aims to improve safety, efficacy, biodistribution, and cost compared to traditional viral gene therapies, and is applicable across multiple organs as demonstrated in preclinical and clinical settings. The company differentiates itself with a nonviral, ultrasound-guided method that addresses common gene therapy challenges and leverages its proprietary platform to bring next-generation genetic medicines to patients. The goal is to commercialize a safe, effective, and affordable gene therapy platform that can deliver genetic medicines to patients in need.
Company Size
51-200
Company Stage
Series A
Total Funding
$60.8M
Headquarters
South San Francisco, California
Founded
2022
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Unlimited Paid Time Off
Gym Membership
Commuter Benefits
Company Equity
SonoThera presents new preclinical data at MDA 2026 highlighting RIPPLE(TM) as an efficient, scalable, nonviral platform for full-length dystrophin delivery in DMD. * RIPPLE(TM)(Remote Induction of Pulsed Pressure Lateral to Energy) is a proprietary ultrasound-mediated delivery technology. * RIPPLE(TM) has been developed to enable efficient, redosable, targeted, and safe delivery of a diverse range of genetic medicines with broad tissue biodistribution, including skeletal, cardiac, and diaphragm muscles. SAN FRANCISCO-(BUSINESS WIRE)-SonoThera(TM), a biotechnology company dedicated to addressing the root causes of disease through next-generation genetic medicines, today announced it will present at the annual Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11th in Orlando, Florida. RIPPLE(TM) has been developed to enable efficient, redosable, targeted, and safe delivery of a diverse range of genetic medicines with broad tissue biodistribution, including skeletal, cardiac, and diaphragm muscles. Share The oral presentation will highlight SonoThera's proprietary RIPPLE(TM)(Remote Induction of Pulsed Pressure Lateral to Energy) technology and its ability to enable delivery of genetic payloads encoding full-length human dystrophin. Data demonstrate robust protein expression across affected muscle groups in Duchenne Muscular Dystrophy (DMD) models, including skeletal, cardiac, and diaphragm muscle. SonoThera has optimized its RIPPLE(TM) technology across multiple rodent and non-human primate (NHP) models and generated compelling translational data supporting broad, highly targeted biodistribution of diverse genetic payloads - without size constraints. The platform is designed to be redosable, durable, well-tolerated, and scalable, addressing key limitations associated with viral delivery approaches. "One of the central challenges in DMD gene therapy has been achieving efficient delivery of full-length dystrophin in a manner that is safe, scalable, and redosable," said Ken Greenberg, PhD, CEO of SonoThera. "We believe RIPPLE(TM) has the potential to address these limitations through a nonviral, noninvasive approach, and we look forward to sharing our latest data with the DMD community at MDA 2026." Presentation Details: Title: Non-Viral Gene Replacement Therapy for DMD Utilizing RIPPLE Ultrasound Mediated Delivery of a Transgene Expressing Full-Length Human Dystrophin Presenter: Ivan Krivega, PhD, VP of Gene Therapy, SonoThera Oral Presentation Number: 271 O Date & Time: Tuesday, March 10th, 4:30 pm - 6:00 pm ET Location: Hilton Orlando, Orlando, FL in Orange ABC room Full conference agenda can be found here. About SonoThera(TM) SonoThera is a biotechnology company dedicated to treating root causes of disease through next-generation genetic medicines. Our nonviral technology is designed to overcome all prevailing limitations of genetic medicine, enabling a pipeline of products which leverages our novel capabilities. Using ultrasound-mediated delivery (UMD), we are developing a proprietary, non-invasive approach which enables broad, highly targeted biodistribution, delivery of diverse genetic payloads without size restriction, in a redosable manner designed to be safe, well-tolerated and cost-effective. Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera is headquartered in South San Francisco. Contacts. Investor Inquiries: Media Inquiries: SonoThera Corporate Communications Elizabeth Harness, P: +1 585-435-7379, [email protected] More News From SonoThera SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-SonoThera(TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15. Since 2022, SonoThera has developed and established its proprietary RIPPLE(TM) technology and optimized it across multiple non-human pri... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-SonoThera(TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida. SonoThera's oral presentation focuses on the safe delivery of DNA expression vectors to the liver in non-human primate (NHP) models using... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-SonoThera(TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the American Society of Nephrology's annual meeting being held November 5-9 in Houston, Texas. The poster presentation focuses on treating XLAS using SonoThera's proprietary RIPPLETM ultrasound-mediated delivery (UMD) technology by delivering a full-length Col4a...
Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced a strategic collaboration with SonoThera, Inc., a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy.
SonoThera™, a biotech company dedicated to treating human diseases through genetic therapy, has completed its $60.75M Series A financing round.
Sonothera Inc. reeled in $60.75 million in a series A financing led by Arch Venture Partners.